Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pacific Horizon: Encouraging Mutations in the Venture Model

This article was originally published in Start Up

Executive Summary

Pacific Horizon is an active venture investor, often owning large majority stakes in its portfolio companies. The venture capitalist has taken two different strategies with its majority-owned virology investments, Illumigen and Koronis, eschewing and embracing risk, respectively. Each firm, however, represents a potential game-changing opportunity, and illustrates PHV's back-to-basics venture philosophy: making novel-mechanism bets that are perceived as having both high scientific risks and long-term potential paybacks

You may also be interested in...



In HIV Research, A Race For The Cure Is Back On Track

Hopes for a vaccine or cure for HIV/AIDS have been dashed before. But recent scientific advances and greater understanding of the limits of antiretroviral drugs have reignited optimism. Just don't expect VCs to get on board.

In HIV Research, A Race For The Cure Is Back On Track

Hopes for a vaccine or cure for HIV/AIDS have been dashed before. But recent scientific advances and greater understanding of the limits of antiretroviral drugs have reignited optimism. Just don't expect VCs to get on board.

The New World for New Drug Approvals: Evolution in Strategies for Getting FDA Drug Approvals

Pharma is adjusting rapidly to a new regulatory world: one in which post-marketing risk management plans change the relationship of the company to doctors and patients and one where FDA's expectations for pre-marketing information about product markets are likely to expand dramatically.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel